Latest news with #MissionBio
Yahoo
21-05-2025
- Health
- Yahoo
Nature Publication Shows Mission Bio's Tapestri® Platform Enables Real-Time, Single-Cell Tracking of Precancerous Clones Using Natural Epigenetic Markers
Epigenetic barcoding incorporating Tapestri unlocks high-throughput single-cell lineage tracing of clonality with or without mutation drivers, a previously invisible precursor to cancer development EPI-clone, developed by researchers at Centre for Genomic Regulation and Institute for Research in Biomedicine, tracks clonal dynamics in hematopoiesis with naturally occurring DNA methylation patterns, laying the groundwork for discovering new cancer progression mechanisms and therapeutic targets SOUTH SAN FRANCISCO, Calif., May 21, 2025--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a new publication in Nature leveraging its Tapestri Platform to develop a single-cell barcoding method for high-throughput cell lineage tracing. Study leader Lars Velten and his team at Spain's Centre for Genomic Regulation (CRG), working with a group led by Alejo Rodriguez-Fraticelli at the Institute for Research in Biomedicine (IRB), used Tapestri as a basis to develop EPI-clone, which combines single-cell multi-omics with the readout of naturally occurring DNA methylation patterns as molecular barcodes for tracing clonality – the rapid proliferation of specific cells that precedes development of cancer. The method could be used to identify drug targets on pre-cancer clones that prevent disease progression, like methylation patterns as for epigenetic drugs like DNA methylation transferase inhibitors. Lineage tracing holds the potential to explain how premalignant conditions like clonal hematopoiesis of indeterminate potential (CHIP) and myelodysplastic syndrome (MDS) can progress into hematologic cancers, and how cancerous subclones persist in relapse. Traditional methods for lineage tracing can be complex, low-throughput, or even harmful to normal cellular function. In the paper, titled "Clonal tracing with somatic epimutations reveals dynamics of blood aging," EPI-clone utilizes natural epigenetic patterns that are highly stable over long time scales. Using Mission Bio's Tapestri Platform for high-throughput multi-omics measurement, researchers successfully captured hundreds of clonal differentiation trajectories across 230,358 single cells in both mouse and human hematopoiesis, with dual readout of epimutational barcodes and cell state information. "EPI-clone provides insights into clonal selection during aging, potentially guiding the development of personalized, preventative treatments for diseases like cancers," said Velten. "The scale of our findings could only have been enabled by Tapestri, which allowed us simultaneous observation of single-cell genotype, phenotype, and clone." "The impressive results of this study are a first step toward truly identifying, and therefore understanding, how certain clones contribute to cancer progression before they expand," said Adam Sciambi, Chief Technology Officer at Mission Bio. "We look forward to continued collaboration with the CRG team and others as we support the use of the Tapestri Platform's unique capabilities to make novel discoveries that change the course of disease understanding and treatment." In aging mice, the researchers found that low output of old hematopoietic stem cells (HSCs) is restricted to a small number of expanded clones, while many functionally young clones persist in old age. In human aging, the team showed that clones associated with known clonal hematopoiesis (CH) mutations are part of a broader spectrum of age-related clonal expansions, with and without known driver mutations, displaying similar lineage biases. The results also showed that clonal complexity declines with age, leading to oligoclonal blood production. To learn more about Tapestri and its ability to provide single-cell DNA + protein analysis at unmatched resolution, please visit About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit View source version on Contacts Media Contact Consort Partners for Mission Biomissionbio@
Yahoo
21-05-2025
- Health
- Yahoo
Nature Publication Shows Mission Bio's Tapestri® Platform Enables Real-Time, Single-Cell Tracking of Precancerous Clones Using Natural Epigenetic Markers
Epigenetic barcoding incorporating Tapestri unlocks high-throughput single-cell lineage tracing of clonality with or without mutation drivers, a previously invisible precursor to cancer development EPI-clone, developed by researchers at Centre for Genomic Regulation and Institute for Research in Biomedicine, tracks clonal dynamics in hematopoiesis with naturally occurring DNA methylation patterns, laying the groundwork for discovering new cancer progression mechanisms and therapeutic targets SOUTH SAN FRANCISCO, Calif., May 21, 2025--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a new publication in Nature leveraging its Tapestri Platform to develop a single-cell barcoding method for high-throughput cell lineage tracing. Study leader Lars Velten and his team at Spain's Centre for Genomic Regulation (CRG), working with a group led by Alejo Rodriguez-Fraticelli at the Institute for Research in Biomedicine (IRB), used Tapestri as a basis to develop EPI-clone, which combines single-cell multi-omics with the readout of naturally occurring DNA methylation patterns as molecular barcodes for tracing clonality – the rapid proliferation of specific cells that precedes development of cancer. The method could be used to identify drug targets on pre-cancer clones that prevent disease progression, like methylation patterns as for epigenetic drugs like DNA methylation transferase inhibitors. Lineage tracing holds the potential to explain how premalignant conditions like clonal hematopoiesis of indeterminate potential (CHIP) and myelodysplastic syndrome (MDS) can progress into hematologic cancers, and how cancerous subclones persist in relapse. Traditional methods for lineage tracing can be complex, low-throughput, or even harmful to normal cellular function. In the paper, titled "Clonal tracing with somatic epimutations reveals dynamics of blood aging," EPI-clone utilizes natural epigenetic patterns that are highly stable over long time scales. Using Mission Bio's Tapestri Platform for high-throughput multi-omics measurement, researchers successfully captured hundreds of clonal differentiation trajectories across 230,358 single cells in both mouse and human hematopoiesis, with dual readout of epimutational barcodes and cell state information. "EPI-clone provides insights into clonal selection during aging, potentially guiding the development of personalized, preventative treatments for diseases like cancers," said Velten. "The scale of our findings could only have been enabled by Tapestri, which allowed us simultaneous observation of single-cell genotype, phenotype, and clone." "The impressive results of this study are a first step toward truly identifying, and therefore understanding, how certain clones contribute to cancer progression before they expand," said Adam Sciambi, Chief Technology Officer at Mission Bio. "We look forward to continued collaboration with the CRG team and others as we support the use of the Tapestri Platform's unique capabilities to make novel discoveries that change the course of disease understanding and treatment." In aging mice, the researchers found that low output of old hematopoietic stem cells (HSCs) is restricted to a small number of expanded clones, while many functionally young clones persist in old age. In human aging, the team showed that clones associated with known clonal hematopoiesis (CH) mutations are part of a broader spectrum of age-related clonal expansions, with and without known driver mutations, displaying similar lineage biases. The results also showed that clonal complexity declines with age, leading to oligoclonal blood production. To learn more about Tapestri and its ability to provide single-cell DNA + protein analysis at unmatched resolution, please visit About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit View source version on Contacts Media Contact Consort Partners for Mission Biomissionbio@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21-05-2025
- Health
- Business Wire
Nature Publication Shows Mission Bio's Tapestri ® Platform Enables Real-Time, Single-Cell Tracking of Precancerous Clones Using Natural Epigenetic Markers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a new publication in Nature leveraging its Tapestri Platform to develop a single-cell barcoding method for high-throughput cell lineage tracing. Study leader Lars Velten and his team at Spain's Centre for Genomic Regulation (CRG), working with a group led by Alejo Rodriguez-Fraticelli at the Institute for Research in Biomedicine (IRB), used Tapestri as a basis to develop EPI-clone, which combines single-cell multi-omics with the readout of naturally occurring DNA methylation patterns as molecular barcodes for tracing clonality – the rapid proliferation of specific cells that precedes development of cancer. The method could be used to identify drug targets on pre-cancer clones that prevent disease progression, like methylation patterns as for epigenetic drugs like DNA methylation transferase inhibitors. Lineage tracing holds the potential to explain how premalignant conditions like clonal hematopoiesis of indeterminate potential (CHIP) and myelodysplastic syndrome (MDS) can progress into hematologic cancers, and how cancerous subclones persist in relapse. Traditional methods for lineage tracing can be complex, low-throughput, or even harmful to normal cellular function. In the paper, titled "Clonal tracing with somatic epimutations reveals dynamics of blood aging," EPI-clone utilizes natural epigenetic patterns that are highly stable over long time scales. Using Mission Bio's Tapestri Platform for high-throughput multi-omics measurement, researchers successfully captured hundreds of clonal differentiation trajectories across 230,358 single cells in both mouse and human hematopoiesis, with dual readout of epimutational barcodes and cell state information. 'EPI-clone provides insights into clonal selection during aging, potentially guiding the development of personalized, preventative treatments for diseases like cancers,' said Velten. 'The scale of our findings could only have been enabled by Tapestri, which allowed us simultaneous observation of single-cell genotype, phenotype, and clone.' 'The impressive results of this study are a first step toward truly identifying, and therefore understanding, how certain clones contribute to cancer progression before they expand,' said Adam Sciambi, Chief Technology Officer at Mission Bio. 'We look forward to continued collaboration with the CRG team and others as we support the use of the Tapestri Platform's unique capabilities to make novel discoveries that change the course of disease understanding and treatment.' In aging mice, the researchers found that low output of old hematopoietic stem cells (HSCs) is restricted to a small number of expanded clones, while many functionally young clones persist in old age. In human aging, the team showed that clones associated with known clonal hematopoiesis (CH) mutations are part of a broader spectrum of age-related clonal expansions, with and without known driver mutations, displaying similar lineage biases. The results also showed that clonal complexity declines with age, leading to oligoclonal blood production. To learn more about Tapestri and its ability to provide single-cell DNA + protein analysis at unmatched resolution, please visit About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit
Business Wire
06-05-2025
- Health
- Business Wire
Mission Bio and Integrated DNA Technologies Partner to Advance Single-Cell Precision in CRISPR Genome Editing Analysis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a pioneer in single-cell multi-omics solutions, has partnered with Integrated DNA Technologies (IDT), a global leader in genomics solutions, to introduce an advanced workflow for precise on- and off-target confirmation in gene editing applications. This collaboration integrates IDT's award-winning rhAmpSeq™ technology with Mission Bio's Tapestri ® Platform to provide a comprehensive, high-resolution approach for assessing genome editing outcomes at the single-cell level. Genome editing is crucial for the development of the next wave of cell and gene therapies, enabling precise and multiple genetic modifications. However, ensuring the specificity and efficiency of these edits remains a critical challenge, particularly in cell and gene therapy (CGT) applications. Traditional bulk sequencing methods provide valuable insights into genome editing efficiency, but lack the resolution to capture single-cell heterogeneity, zygosity, and co-occurrence of edits within individual cells. To address these challenges, Mission Bio and IDT have developed an integrated workflow combining IDT's rhAmpSeq amplicon-based targeted resequencing chemistry with Mission Bio's droplet-based single-cell DNA sequencing technology. This novel solution builds on published approaches that researchers have previously used to leverage the platforms. The new, integrated approach enhances the efficiency for obtaining both on-target efficacy assessment and off-target detection in a single-cell context, offering researchers an unprecedented level of accuracy and confidence in genome editing analysis. In a proof-of-concept study, to be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, the integrated workflow was interrogated using well-characterized cell lines and selected for their extensive orthogonal bulk sequencing data. By targeting loci with known indel variations ranging from single-base pair changes to large insertions and deletions (>2,000 bp), the study demonstrated the robustness of rhAmpSeq chemistry in single-cell applications. The resulting targeted panel proved compatible with both bulk and single-cell assays, ensuring seamless adoption across various research needs. 'Our single-cell multi-omics has been used in combination with bulk sequencing to add specificity that otherwise would not be possible,' said Brian Kim, CEO of Mission Bio. 'By integrating our capabilities with IDT's trusted approach to bulk sequencing, we're adding together multiple layers of genetic insights in a single drop.' The Tapestri Platform's automated single-cell genome editing analytics pipeline provided a quantitative assessment of editing efficiency, off-target editing levels and zygosity, offering a critical layer of data resolution beyond bulk sequencing. By integrating rhAmpSeq's advanced primer design with Mission Bio's single-cell DNA resequencing technology, the new workflow establishes a cost-effective, scalable, and highly customizable solution for genome editing validation in CGT applications. 'Safety is key to unlocking the true promise of CRISPR, and this collaboration with Mission Bio reflects another step forward to advancing the delivery of safer and more efficient genome editing platforms,' said Sandy Ottensmann, VP/GM, Gene Writing and Editing at IDT. 'By pairing the precision of rhAmpSeq with the single-cell resolution of Tapestri, we aim to support cell and gene therapy developers in driving the future of safe, life-changing therapies to benefit more patients.' Researchers and industry professionals can learn more about this cutting-edge approach at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting this month. Mission Bio and IDT will be presenting a poster detailing the study's findings, demonstrating the power of integrated single-cell sequencing for genome editing validation. The poster 'Comprehensive On- and Off-target Validation Using Integrated rhAmpSeq and Targeted DNA Resequencing Single-Cell Technology for Gene Editing Applications' will be presented on Thursday, May 15 at 5:30 pm CST. An oral presentation delivered by Dr. Ayal Hendel of Bar-Ilan University, 'Single-Cell Profiling of Genome-Editing Alterations and Functional Outcomes in CRISPR-Engineered Cells,' will take place on Saturday, May 17 at 9:00 am CST. Visit Mission Bio's Booth #1749 at ASGCT to see how this technology can accelerate your research. For more information, visit or contact missionbio@ About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit Disclaimer: For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
